Huihui Mou

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 12 papers. Top paper: “SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity”.

SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity

Nature Communications(2020)10.1038/s41467-020-19808-4

N/A

1.0DataRank · unranked

1066 citations

Cody B. Jackson, Huihui Mou, Amrita Ojha, Haiyong Peng, Brian D. Quinlan +10 more

The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.06.12.148726

N/A

0DataRank · unranked

612 citations

Cody B. Jackson, Huihui Mou, Amrita Ojha, Erumbi S. Rangarajan, Tina Izard +3 more

An engineered receptor-binding domain improves the immunogenicity of multivalent SARS-CoV-2 vaccines

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.11.18.388934

N/A

0DataRank · unranked

8 citations

Wenhui He, Huihui Mou, Lizhou Zhang, Yan Guo, Jing Chang +10 more

Rapid, simplified whole blood-based multiparameter assay to quantify and phenotype SARS-CoV-2 specific T cells

medRxiv(2020)10.1101/2020.10.30.20223099

N/A

0DataRank · unranked

7 citations

Georgia Schäfer, Elsa Du Bruyn, René Goliath, Cari Stek, Huihui Mou +4 more

Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2

PLoS Pathogens(2021)10.1371/journal.ppat.1009212

N/A

0DataRank · unranked

223 citations

Huihui Mou, Lizhou Zhang, Amrita Ojha, Hyeryun Choe, Michael Farzan +1 more

A more efficient CRISPR-Cas12a variant derived from Lachnospiraceae bacterium MA2020

Molecular Therapy — Nucleic Acids(2021)10.1016/j.omtn.2021.02.012

N/A

0DataRank · unranked

41 citations

HaJeung Park, Christopher L. Nobles, Pabalu P. Karunadharma, Li Pan, Guocai Zhong +9 more

An Engineered Receptor-Binding Domain Improves the Immunogenicity of Multivalent SARS-CoV-2 Vaccines

mBio(2021)10.1128/mbio.00930-21

N/A

0DataRank · unranked

28 citations

Wenhui He, Huihui Mou, Lizhou Zhang, Jing Chang, Shoujiao Peng +10 more

Engineering well-expressed, V2-immunofocusing HIV-1 envelope glycoprotein membrane trimers for use in heterologous prime-boost vaccine regimens

PLoS Pathogens(2021)10.1371/journal.ppat.1009807

N/A

0DataRank · unranked

19 citations

Francisco Almanza, Alessio D’Addabbo, E. Duggan, Jinsong Zhang, Kshitij Wagh +12 more

Donor Anti-Spike Immunity is Related to Recipient Recovery and Can Predict the Efficacy of Convalescent Plasma Units

medRxiv(2021)10.1101/2021.02.25.21252463

N/A

0DataRank · unranked

5 citations

William R. Hartman, Huihui Mou, Michael Farzan, Susan L. Stramer, Erin Goodhue +4 more

Identification of potent small molecule inhibitors of SARS-CoV-2 entry

SLAS DISCOVERY(2022)10.1016/j.slasd.2021.10.012

N/A

0DataRank · unranked

32 citations

Huihui Mou, Yuka Otsuka, Joseph Jablonski, Robert S. Adcock, Lalit Batra +19 more

Cytoplasmic Tail Truncation Stabilizes S1-S2 Association and Enhances S Protein Incorporation into SARS-CoV-2 Pseudovirions

Journal of Virology(2023)10.1128/jvi.01650-22

N/A

0DataRank · unranked

8 citations

Nancy Hom, Amrita Ojha, Klaus N. Lovendahl, Huihui Mou, Kelly K. Lee +2 more

Simultaneous screening for selective SARS-CoV-2, Lassa, and Machupo virus entry inhibitors

SLAS DISCOVERY(2024)10.1016/j.slasd.2024.100178

N/A

0DataRank · unranked

5 citations

Lizhou Zhang, Huihui Mou, Justin Shumate, Claire E. Kitzmiller, Louis Scampavia +5 more